With the enactment of major drug pricing reform—including the Inflation Reduction Act (IRA), which arguably made the most significant changes to U.S. prescription drug pricing regulations in history—the reporting of drug prices is more critical than ever for determining reimbursement for drugs and establishing potential manufacturer payment obligations to various government agencies. In a new webinar, Manatt Health will explore how federal and state governments plan to use the drug pricing information reported by both manufacturers and providers, examine new reporting obligations at the federal and state levels, and provide key strategies for successfully navigating today’s changing landscape. Click here to register free—and earn CLE. Key topics include:
- How the government will use information that manufacturers currently report to determine new rebate and discount obligations under the IRA
- The new information both manufacturers and providers will need to report to the government under federal drug pricing reform
- New obligations manufacturers are facing from state governments
- Litigation impacting the information that must be reported and the penalties for violating reporting requirements
- Risks for reporting noncompliance and strategies to minimize those risks
Even if you can’t make our live program on March 23, click here to register free now, and you’ll receive a link to view the webinar on demand.
Kristen Bernie, Deputy Vice President, PhRMA
Brian Bewley, Partner, Manatt Health
Alex Dworkowitz, Partner, Manatt Health
Matthew Itzkowitz, Associate, Manatt Health
Date and Time:
Thursday, March 23
1:00–2:00 p.m. ET
Click here to register free.
This program has been approved for 1.0 NY CLE Skills (transitional and non-transitional) and for 1.0 CA MCLE General credit.
If you would like to receive an audio transcript of this webinar due to accessibility issues, please email us at firstname.lastname@example.org.
This program does not constitute legal advice, nor does it establish an attorney-client relationship. Views expressed by presenters are strictly their own and should not be construed to be the views of Manatt or attributed to Manatt.